3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
18
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
8
Fallopian Tube Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma
2
Lung Neoplasms
2
Hodgkin Disease
2
Fanconi Anemia, Complementation Group D1
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Advanced Cancer
2
Triple Negative Metastatic Breast Cancer
1
Thymoma
1
Thrombocytosis
1
Solid Tumor
1
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Rutin
1
Gemcitabine
1
Cisplatin
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Muscle Invasive Bladder Cancer
×
olaparib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled